Factors Associated With Weight Gain in People Treated With Dolutegravir.
HIV metabolic complications
TAF
TDF
dolutegravir
weight gain
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
16
03
2020
accepted:
22
05
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens. Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for weight increases >10% from baseline. A total of 713 participants, 25.3% women and 91% Caucasian, were included. Of these, 195 (27.4%) started DTG as their first ART regimen, whereas 518 (72.6%) were ART-experienced. DTG was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide (TAF)/FTC in 59. At 6 and 12 months, weight gain was highest among PWH on TDF/FTC+DTG and TAF/FTC+DTG. Baseline CD4 <200 cells/mm Naïve PWH with lower CD4 counts and those on TAF/FTC or TDF/FTC backbones were at higher risk of weight increase in the course of DTG-based ART.
Sections du résumé
BACKGROUND
BACKGROUND
An unexpected excess in weight gain has recently been reported in the course of dolutegravir (DTG) treatment. The aim of the present study was to investigate whether weight gain differs among different DTG-containing regimens.
METHODS
METHODS
Adult naïve and experienced people with HIV (PWH) initiating DTG-based antiretroviral therapy (ART) between July 2014 and December 2019 in the Surveillance Cohort Long-Term Toxicity Antiretrovirals (SCOLTA) prospective cohort were included. We used an adjusted general linear model to compare weight change among backbone groups and a Cox proportional hazard regression model to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for weight increases >10% from baseline.
RESULTS
RESULTS
A total of 713 participants, 25.3% women and 91% Caucasian, were included. Of these, 195 (27.4%) started DTG as their first ART regimen, whereas 518 (72.6%) were ART-experienced. DTG was associated with abacavir/lamivudine in 326 participants, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 148, boosted protease inhibitors in 60, rilpivirine in 45, lamivudine in 75, and tenofovir alafenamide (TAF)/FTC in 59. At 6 and 12 months, weight gain was highest among PWH on TDF/FTC+DTG and TAF/FTC+DTG. Baseline CD4 <200 cells/mm
CONCLUSIONS
CONCLUSIONS
Naïve PWH with lower CD4 counts and those on TAF/FTC or TDF/FTC backbones were at higher risk of weight increase in the course of DTG-based ART.
Identifiants
pubmed: 32577427
doi: 10.1093/ofid/ofaa195
pii: ofaa195
pmc: PMC7295329
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa195Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Antivir Ther. 2012;17(7):1281-9
pubmed: 22951353
Infection. 2019 Feb;47(1):95-102
pubmed: 30269210
AIDS. 2013 Aug 24;27(13):2069-79
pubmed: 24384588
Lancet. 2014 Aug 30;384(9945):766-81
pubmed: 24880830
PLoS One. 2019 Oct 11;14(10):e0223181
pubmed: 31603906
BMC Infect Dis. 2011 Sep 20;11:246
pubmed: 21933422
Int J STD AIDS. 2007 Mar;18(3):184-7
pubmed: 17362552
AIDS. 2020 May 1;34(6):877-881
pubmed: 32271252
HIV Med. 2018 Nov;19(10):724-733
pubmed: 30101539
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
Infect Drug Resist. 2019 May 23;12:1385-1391
pubmed: 31213857
AIDS. 2017 Jun 19;31(10):1499-1500
pubmed: 28574967
AIDS. 2019 Dec 1;33(15):2387-2391
pubmed: 31764103
Clin Infect Dis. 2020 Mar 17;70(7):1267-1274
pubmed: 31100116
Clin Infect Dis. 2020 Jan 2;70(2):319-322
pubmed: 31125395
Clin Infect Dis. 2019 Oct 14;:
pubmed: 31606734
Nutrients. 2013 Feb 07;5(2):498-508
pubmed: 23434905
AIDS. 2017 Nov 28;31(18):2503-2514
pubmed: 29112070
BMC Infect Dis. 2018 Jul 31;18(1):357
pubmed: 30064371
Clin Infect Dis. 2020 Feb 26;:
pubmed: 32099991
AIDS. 2018 Apr 24;32(7):903-912
pubmed: 29424784
J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531
pubmed: 28825943
N Engl J Med. 2019 Aug 29;381(9):803-815
pubmed: 31339677
Clin Infect Dis. 2015 Jun 15;60(12):1852-9
pubmed: 25761868
New Microbiol. 2018 Oct;41(4):247-255
pubmed: 30604833
J Antimicrob Chemother. 2018 Aug 1;73(8):2177-2185
pubmed: 29722811
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):317-20
pubmed: 15980692
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):458-66
pubmed: 16980905
Open Forum Infect Dis. 2017 Nov 03;4(4):ofx239
pubmed: 29255735
J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):426-31
pubmed: 17514013
AIDS. 2020 Jan 1;34(1):109-114
pubmed: 31567162
Clin Infect Dis. 2009 Nov 15;49(10):1591-601
pubmed: 19842973